The European Medicines Agency has had to revise its forecasts for drug approval applications submitted via the centralised procedure this year after generic filings outstripped expectations in the first half.
For the whole year, the EMEA had expected 109 applications in total; it has now raised that to 127, mainly because of an unexpected increase in the number of generic filings in the first half to 31...
Please login to read the full article.
